68Ga成纤维细胞激活蛋白抑制剂PET/CT检测转移性甲状腺癌:与18F-FDG PET/CT的比较
前瞻性纳入35例临床疑似或确诊转移性分化型甲状腺癌患者,行配对68Ga-FAPI与18F-FDG PET/CT,以组织病理学和临床随访(平均12个月±0.7)为参考标准;68Ga-FAPI PET/CT对颈部病变和远处转移的敏感性均高于18F-FDG PET/CT。
要点
- 68Ga-FAPI PET/CT对颈部病变敏感性83%(65/78),高于18F-FDG的65%(51/78),P=.01。
- 68Ga-FAPI PET/CT对远处转移敏感性79%(87/110),高于18F-FDG的59%(65/110),P<.001。
- 转移性侧区淋巴结、腋窝淋巴结、纵隔淋巴结及肺转移灶的68Ga-FAPI SUVmax均高于18F-FDG。
核心结论
- 68Ga-FAPI PET/CT在显示转移性分化型甲状腺癌方面优于18F-FDG PET/CT,尤其在淋巴结和肺转移方面。
研究设计与样本
- 前瞻性研究,2020年5月至8月纳入35例临床疑似或确诊转移性分化型甲状腺癌患者,行配对68Ga-FAPI与18F-FDG PET/CT,以组织病理学结果和临床随访(平均12个月±0.7,范围11-13个月)为最终诊断参考标准。
关键影像表现/征象
- 转移性侧区淋巴结68Ga-FAPI SUVmax为6.0,高于18F-FDG的3.5(P=.001)。
- 腋窝淋巴结68Ga-FAPI SUVmax为8.5,高于18F-FDG的4.3(P=.01)。
- 纵隔淋巴结68Ga-FAPI SUVmax为9.1,高于18F-FDG的5.0(P=.001)。
- 肺转移灶68Ga-FAPI SUVmax为1.7,高于18F-FDG的1.1(P=.004)。
诊断标准与关键数值
- 68Ga-FAPI PET/CT对颈部病变敏感性83%(65/78;95%CI:73,90),18F-FDG PET/CT为65%(51/78;95%CI:54,75),P=.01。
- 68Ga-FAPI PET/CT对远处转移敏感性79%(87/110;95%CI:71,86),18F-FDG PET/CT为59%(65/110;95%CI:50,68),P<.001。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
Background Gallium 68 (68Ga)-labeled fibroblast activation protein inhibitor (FAPI) has been proposed as a potential radiotracer for visualizing cancerous lesions, but its utility for identifying metastatic differentiated thyroid cancer (DTC) is not well established in the literature. Purpose To evaluate the clinical utility of 68Ga-FAPI PET/CT for detecting metastatic DTC and to compare the results with those of fluorine 18 (18F) fluorodeoxyglucose (FDG) PET/CT. Materials and Methods Participants with clinically suspected or confirmed metastatic DTC were prospectively enrolled and underwent paired 68Ga-FAPI and 18F-FDG PET/CT from May to August 2020. Histopathologic results and clinical follow-up (mean, 12 months ± 0.7 [SD]; range, 11-13 months) were used as reference standards for the final diagnosis. 18F-FDG and 68Ga-FAPI uptake was compared by using the Wilcoxon signed-rank test. The McNemar test was used to compare the diagnostic accuracy of the two techniques, and the influence of various clinicopathologic characteristics on 18F-FDG and 68Ga-FAPI uptake was evaluated with Mann-Whitney and Kruskal-Wallis tests. Results In total, 35 participants (median age, 44 years; IQR, 28-58 years; 18 [51%] men) were evaluated. In all 35 participants, the 68Ga-FAPI-derived maximum standardized uptake value (SUVmax) was higher than the 18F-FDG-derived SUVmax in the metastatic lateral compartment (6.0 vs 3.5; P = .001), axillary (8.5 vs 4.3; P = .01), mediastinal lymph nodes (9.1 vs 5.0; P = .001), and pulmonary metastases (1.7 vs 1.1; P = .004). 68Ga-FAPI PET/CT had a higher sensitivity than 18F-FDG PET/CT for depicting neck lesions (83% [65 of 78; 95% CI: 73, 90] vs 65% [51 of 78; 95% CI: 54, 75], P = .01) and distant metastases (79% [87 of 110; 95% CI: 71, 86] vs 59% [65 of 110; 95% CI: 50, 68], P < .001). Conclusion Gallium 68-labeled fibroblast activation protein inhibitor PET/CT was superior to fluorine 18 fluorodeoxyglucose PET/CT for depicting metastatic differentiated thyroid cancer, especially in lymph nodes and pulmonary metastases. Published under a CC BY 4.0 license. Online supplemental material is available for this article.
引用
- Fu, Wu, Huang, et al. 68Ga Fibroblast Activation Protein Inhibitor PET/CT in the Detection of Metastatic Thyroid Cancer: Comparison with 18F-FDG PET/CT. Radiology. 2022. PMID: 35536131. doi:10.1148/radiol.212430
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。